AC
VTGN icon

Armistice Capital’s VistaGen Therapeutics VTGN Stock Holding History

Armistice Capital’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-300,000
Closed -$1.04M – 322
2024
Q2 		$1.04M Sell
300,000
-64,000
-18% -$277K 0.01% 161
2024
Q1 		$1.92M Sell
364,000
-114,000
-24% -$548K 0.03% 145
2023
Q4 		$2.46M Buy
+478,000
New +$1.81M 0.03% 148

Other funds holding VTGN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Armistice Capital's VTGN Position: Q3 2024 in Review

Armistice Capital sold out of VistaGen Therapeutics (VTGN) in Q3 2024, closing a stake of 300,000 shares — an estimated $1.04M sold.

Armistice Capital first reported a position in VTGN in Q4 2023 and held it in 3 quarters. The position peaked at $2.46M in Q4 2023. 47 funds tracked by Wall St. Rank hold VTGN as of Q3 2024.

  • Armistice Capital reported no remaining VistaGen Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Armistice Capital sold 300,000 VistaGen Therapeutics shares in Q3 2024, an estimated $1.04M.
  • Armistice Capital first reported a position in VistaGen Therapeutics in Q4 2023 and held it in 3 quarters.
  • Armistice Capital's VistaGen Therapeutics position peaked at $2.46M in Q4 2023.
  • 47 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2024.

Based on Armistice Capital's 13F filing for Q3 2024, filed 14 Nov 2024.